Published in Gene Therapy Weekly, May 17th, 2007
Avecia will officially unveil the addition of pAVEway to its growing portfolio of advanced technology solutions for the manufacture of therapeutic proteins at the BIO 2007 convention in Boston, Massachusetts (7-9 May).
The new technology enables class-leading (>10g/L) microbial production of a wide range of therapeutically useful proteins (vaccines, cytokines, growth factors, etc).
pAVEway will also help to reduce the time to market and cost, while increasing flexibility and maintaining Avecia's high quality...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly